Utility of T1-weighted MRI as a predictor of liver lesion visibility on ultrasound: A clinical tool to determine feasibility of ultrasound-guided percutaneous interventions. Issue 90 (May 2017)

• Record Type: Journal Article
• Authors: Miao, Timothy L.; Kielar, Ania Z.; Hibbert, Rebecca M.; Schieda, Nicola
• Is Part Of: European journal of radiology. Issue 90(2017)
• Page Start: 256
• Page End: 261
• Publication Date: 2017-05
• Subjects: FLL focal liver lesion -- US ultrasound -- MRI magnetic resonance imaging -- FS-T1W-GRE fat-suppressed T1-weighted gradient recalled echo -- SI signal intensity -- HCC hepatocellular carcinoma -- RFA radiofrequency ablation; Liver -- Magnetic resonance imaging -- Ultrasound -- Intervention; Medical radiology -- Periodicals; Radiology -- Periodicals; Radiologie médicale -- Périodiques; Medical radiology; Periodicals; 616.075705
• DOI: 10.1016/j.ejrad.2017.03.004
• Languages: English
• ISSNs: 0720-048X

Abstract

Highlights: FLL of smaller size and with T1W isointensity to surrounding liver parenchyma are associated with sonographic non-visibility. T1W isointensity more accurately predicts US non-visibility in non-steatotic livers. FLL size measurement and T1W isointensity can help plan US-guided interventions for FLL. Abstract: Purpose: To determine the utility of fat-suppressed T1-weighted gradient recalled echo (FS-T1W-GRE) MRI to predict visibility of focal liver lesions (FLL) on abdominal ultrasound (US). Materials and methods: With IRB approval, between 2010 and 2013, 109 patients (28.4% females, age 66.9 ± 10.9 years) with 177 FLL (hepatocellular carcinoma = 132, metastases = 44, other = 1) underwent MRI and prospective, radiologist-performed treatment-planning US (to determine eligibility for US-guided ablation). MRI examinations were reviewed by a blinded radiologist who assessed: a) size and location of FLL, b) presence of hepatic steatosis on dual-echo T1W-GRE, and c) quantitative signal intensity of FLL relative to liver on FS-T1W-GRE. Associations between MR imaging findings and visibility on US were assessed using independent t -tests and the chi-squares test. Results: 69.5% (123/177) FLL were identified with US and 30.5% (54/177) were not visible. Size of FLL on MRI was associated with visibility on US (p < 0.0001) with no association between FLL visibility on US and segmental or subcapsular location (p = 0.29 and p = 0.25, respectively). 20.2% (22/109) patients had hepatic steatosis on MRI, which was not associated with non-visibility of FLL on US (p = 0.67). 38.4% (68/177) FLL were isointense to liver on FS-T1W-GRE which was associated with non-visibility on US (p = 0.036) particularly in non-steatotic livers (p = 0.014). Conclusion: FLL size and isointensity of FLL to liver parenchyma on FS-T1W-GRE MRI are associated with non-visibility on US, particularly in non-steatotic livers. These results have implications when planning US-guided percutaneous interventions of FLL detected with MRI.